FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382044804> ?p ?o ?g. }

• W4382044804 endingPage "1086" @default.
• W4382044804 startingPage "1073" @default.
• W4382044804 abstract "Abstract Targeted alpha therapies (TAT) are an innovative class of therapies for cancer treatment. The unique mode-of-action of TATs is the induction of deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as gynecologic cancers upregulating the chemoresistance P-glycoprotein (p-gp) and overexpressing the membrane protein mesothelin (MSLN), are promising targets for TATs. Here, based on the previous encouraging findings with monotherapy, we investigated the efficacy of the mesothelin-targeted thorium-227 conjugate (MSLN-TTC) both as monotherapy and in combination with chemotherapies and antiangiogenic compounds in ovarian and cervical cancer models expressing p-gp. MSLN-TTC monotherapy showed equal cytotoxicity in vitro in p-gp–positive and -negative cancer cells, while chemotherapeutics dramatically lost activity on p-gp–positive cancer cells. In vivo, MSLN-TTC exhibited dose-dependent tumor growth inhibition with treatment/control ratios of 0.03–0.44 in various xenograft models irrespective of p-gp expression status. Furthermore, MSLN-TTC was more efficacious in p-gp–expressing tumors than chemotherapeutics. In the MSLN-expressing ST206B ovarian cancer patient-derived xenograft model, MSLN-TTC accumulated specifically in the tumor, which combined with pegylated liposomal doxorubicin (Doxil), docetaxel, bevacizumab, or regorafenib treatment induced additive-to-synergistic antitumor efficacy and substantially increased response rates compared with respective monotherapies. The combination treatments were well tolerated and only transient decreases in white and red blood cells were observed. In summary, we demonstrate that MSLN-TTC treatment shows efficacy in p-gp–expressing models of chemoresistance and has combination potential with chemo- and antiangiogenic therapies." @default.
• W4382044804 created "2023-06-27" @default.
• W4382044804 creator A5005148708 @default.
• W4382044804 creator A5006335909 @default.
• W4382044804 creator A5006783007 @default.
• W4382044804 creator A5009359386 @default.
• W4382044804 creator A5016955536 @default.
• W4382044804 creator A5017327688 @default.
• W4382044804 creator A5033560120 @default.
• W4382044804 creator A5034373024 @default.
• W4382044804 creator A5037599842 @default.
• W4382044804 creator A5056198089 @default.
• W4382044804 creator A5058059489 @default.
• W4382044804 creator A5063128206 @default.
• W4382044804 creator A5072394114 @default.
• W4382044804 creator A5072570184 @default.
• W4382044804 creator A5082071316 @default.
• W4382044804 date "2023-06-26" @default.
• W4382044804 modified "2023-09-27" @default.
• W4382044804 title "A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies" @default.
• W4382044804 cites W1954597686 @default.
• W4382044804 cites W1968209756 @default.
• W4382044804 cites W1971837077 @default.
• W4382044804 cites W1972160506 @default.
• W4382044804 cites W1981376295 @default.
• W4382044804 cites W2016318120 @default.
• W4382044804 cites W2019607817 @default.
• W4382044804 cites W2022095438 @default.
• W4382044804 cites W2035248522 @default.
• W4382044804 cites W2038320131 @default.
• W4382044804 cites W2044774111 @default.
• W4382044804 cites W2050912869 @default.
• W4382044804 cites W2060993743 @default.
• W4382044804 cites W2088659772 @default.
• W4382044804 cites W2094586578 @default.
• W4382044804 cites W2103562758 @default.
• W4382044804 cites W2111358509 @default.
• W4382044804 cites W2116922255 @default.
• W4382044804 cites W2138654358 @default.
• W4382044804 cites W2147834058 @default.
• W4382044804 cites W2154200023 @default.
• W4382044804 cites W2161962458 @default.
• W4382044804 cites W2168709731 @default.
• W4382044804 cites W2254640582 @default.
• W4382044804 cites W2489035057 @default.
• W4382044804 cites W2560499218 @default.
• W4382044804 cites W2753722921 @default.
• W4382044804 cites W2772038399 @default.
• W4382044804 cites W2772085397 @default.
• W4382044804 cites W2792755823 @default.
• W4382044804 cites W2794128499 @default.
• W4382044804 cites W2891647981 @default.
• W4382044804 cites W2897984531 @default.
• W4382044804 cites W2917476978 @default.
• W4382044804 cites W2921520187 @default.
• W4382044804 cites W2944344108 @default.
• W4382044804 cites W2965404853 @default.
• W4382044804 cites W2992107509 @default.
• W4382044804 cites W2996077865 @default.
• W4382044804 cites W3015002607 @default.
• W4382044804 cites W3082918087 @default.
• W4382044804 cites W3092122627 @default.
• W4382044804 cites W3128646645 @default.
• W4382044804 cites W3149678565 @default.
• W4382044804 cites W3164081628 @default.
• W4382044804 cites W3203731043 @default.
• W4382044804 cites W4211203170 @default.
• W4382044804 cites W4220785729 @default.
• W4382044804 cites W4310051805 @default.
• W4382044804 doi "https://doi.org/10.1158/1535-7163.mct-22-0808" @default.
• W4382044804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37365121" @default.
• W4382044804 hasPublicationYear "2023" @default.
• W4382044804 type Work @default.
• W4382044804 citedByCount "0" @default.
• W4382044804 crossrefType "journal-article" @default.
• W4382044804 hasAuthorship W4382044804A5005148708 @default.
• W4382044804 hasAuthorship W4382044804A5006335909 @default.
• W4382044804 hasAuthorship W4382044804A5006783007 @default.
• W4382044804 hasAuthorship W4382044804A5009359386 @default.
• W4382044804 hasAuthorship W4382044804A5016955536 @default.
• W4382044804 hasAuthorship W4382044804A5017327688 @default.
• W4382044804 hasAuthorship W4382044804A5033560120 @default.
• W4382044804 hasAuthorship W4382044804A5034373024 @default.
• W4382044804 hasAuthorship W4382044804A5037599842 @default.
• W4382044804 hasAuthorship W4382044804A5056198089 @default.
• W4382044804 hasAuthorship W4382044804A5058059489 @default.
• W4382044804 hasAuthorship W4382044804A5063128206 @default.
• W4382044804 hasAuthorship W4382044804A5072394114 @default.
• W4382044804 hasAuthorship W4382044804A5072570184 @default.
• W4382044804 hasAuthorship W4382044804A5082071316 @default.
• W4382044804 hasBestOaLocation W43820448041 @default.
• W4382044804 hasConcept C104317684 @default.
• W4382044804 hasConcept C109316439 @default.
• W4382044804 hasConcept C121608353 @default.
• W4382044804 hasConcept C126322002 @default.
• W4382044804 hasConcept C150903083 @default.
• W4382044804 hasConcept C182979987 @default.
• W4382044804 hasConcept C185592680 @default.

• next